Currently, there are 69.61M common shares owned by the public and among those 58.32M shares have been available to trade.
The company’s stock has a 5-day price change of 105.69% and 80.36% over the past three months. AKRO shares are trading 85.87% year to date (YTD), with the 12-month market performance up to 136.44% higher. It has a 12-month low price of $15.32 and touched a high of $37.00 over the same period. AKRO has an average intraday trading volume of 718.90K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 89.72%, 77.52%, and 98.02% respectively.
Institutional ownership of Akero Therapeutics Inc (NASDAQ: AKRO) shares accounts for 97.86% of the company’s 69.61M shares outstanding.
It has a market capitalization of $3.61B and a beta (3y monthly) value of -0.21. The earnings-per-share (ttm) stands at -$3.75. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.70% over the week and 5.93% over the month.
Earnings per share for the fiscal year are expected to decrease by -34.66%, and -20.28% over the next financial year. EPS should shrink at an annualized rate of -17.92% over the next five years, compared to 1.03% over the past 5-year period.
Looking at the support for the AKRO, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on January 27, 2025, with the firm’s price target at $50-$72. Citigroup coverage for the Akero Therapeutics Inc (AKRO) stock in a research note released on November 18, 2024 offered a Buy rating with a price target of $65. BofA Securities was of a view on April 22, 2024 that the stock is Neutral, while Cantor Fitzgerald gave the stock Overweight rating on September 19, 2023, issuing a price target of $69. UBS on their part issued Buy rating on August 28, 2023.
